relapsed small cell lung cancer
Conditions
Interventions
The treatment schedule included carboplatin, diluted with 500 ml of normal saline, given intravenously over 90 minutes on day 5, and topotecan with 100 ml of normal saline, given intravenously over 30
Sponsors
West Japan Oncology Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with histologic or cytologic confirmation of SCLC who received one prior chemotherapy regimen were eligible. The eligibility criteria were as follows; (1) measurable lesions; (2) age ≥ 20, <75; (3) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; (4) adequate organ function
Exclusion criteria
Exclusion criteria: The exclusion criteria consisted of pulmonary fibrosis or interstitial pneumonitis with symptoms or apparent abnormalities on chest X-ray, massive pleural effusion or ascites, acute inflammation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, severe heart disease, cerebrovascular disease, uncontrollable diabetes mellitus, severe infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to establish MTD and to determine the RD. | — |
Countries
Japan
Contacts
Public ContactShinichiro Nakamura
Hyogo Medical Center for Adults Department of Medical Oncology
Outcome results
None listed